Drug Profile
WIN 68210
Alternative Names: SW 68210Latest Information Update: 06 Aug 2002
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Developer Nonindustrial sources; Sanofi-Synthelabo
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo
- 02 Jun 1999 New profile
- 02 Jun 1999 Preclinical development for Cancer in USA (Unknown route)